BHVN
Biohaven Ltd.
Biotechnology · Healthcare · United States
15.42
close · 2026-10-30
value
27
cheaper than peers27
quality
4
stronger fundamentals4
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| earnings yield, 2 years ago | -37.2% | 53 |
| cash flow yield, 2 years ago | -14.4% | 50 |
| cash flow yield, 3 years ago | -14.5% | 50 |
| earnings yield, 3 years ago | -82.7% | 43 |
| cash flow yield, 1 year ago | -25.2% | 42 |
| cash flow yield, latest year | -26.2% | 38 |
| earnings yield, latest year | -44.5% | 36 |
| earnings yield, 1 year ago | -60.2% | 36 |
| price to book | 39.34× | 4 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 0.0% | 50 |
| return on equity | -799.5% | 1 |
| debt to equity | 2430.3% | 1 |
3 of 4 measures available
Facts
| market cap | $2B |
| free cash flow | -$256.2M |
| employees | 274 |
| first trade | 2022-09-23 |
| next earnings | 2026-10-29 |
| fundamentals updated | 2026-10-29 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -6.86 | -9.28 | -5.73 | -12.75 |
| free cash flow | -$610.2M | -$586.5M | -$334.8M | -$338.8M |
| net income | -$738.8M | -$846.4M | -$408.2M | -$570.3M |
| revenue | $0 | $0 | $0 | $0 |